Advertising

Novavax Inc

NVAX-Q

NASDAQ:NVAX

203.24
6.65 (3.17%)
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden.
More at Wikipedia

Analysis and Opinions about NVAX-Q

Signal
Opinion
Expert
Chart
TOP PICK
TOP PICK
July 22, 2021
Stockchase Research Editor: Michael O'Reilly NVAX is applying for Emergency Use Authorization for its COVID-19 vaccine as experts believe annual boosters may be required as with the annual flu shots. It has achieved over 89% efficacy and does not require deep freeze storage -- a huge advantage. It has agreements already in place for 180 million doses in the UK, Canada, and Australia when approved. We would buy this with a stop loss at $160, looking to achieve $272 -- upside potential over 27%. Yield 0%. (Analysts’ price target is $271.75)
Show full opinionHide full opinion
Novavax Inc (NVAX-Q)
July 22, 2021
Stockchase Research Editor: Michael O'Reilly NVAX is applying for Emergency Use Authorization for its COVID-19 vaccine as experts believe annual boosters may be required as with the annual flu shots. It has achieved over 89% efficacy and does not require deep freeze storage -- a huge advantage. It has agreements already in place for 180 million doses in the UK, Canada, and Australia when approved. We would buy this with a stop loss at $160, looking to achieve $272 -- upside potential over 27%. Yield 0%. (Analysts’ price target is $271.75)
DON'T BUY
DON'T BUY
June 15, 2021
Recently announced an effective Covid vaccine In 2019, they had less than $50 million in revenue. It was nascent and now prominent. They could participate in the booster Covid market, and they need to live up to their current market cap of $14 billion. NVAX has to vaccinate a quarter of the world's population to trade at 1x revenues. There's a lot of hope built into the shares that they succeed. He can't buy this and sleep at night.
Show full opinionHide full opinion
Novavax Inc (NVAX-Q)
June 15, 2021
Recently announced an effective Covid vaccine In 2019, they had less than $50 million in revenue. It was nascent and now prominent. They could participate in the booster Covid market, and they need to live up to their current market cap of $14 billion. NVAX has to vaccinate a quarter of the world's population to trade at 1x revenues. There's a lot of hope built into the shares that they succeed. He can't buy this and sleep at night.
Gordon Reid
Price
$0.000
Owned
No
DON'T BUY
DON'T BUY
May 7, 2021

It's not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Show full opinionHide full opinion

It's not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Jim Cramer - Mad Money
Price
$176.050
Owned
Unknown
DON'T BUY
DON'T BUY
March 18, 2021

NVAX vs. PFE He'd absolutely go with PFE. Investors have been chasing growthy parts of the market and ignoring the stable areas. Vaccines don't move the needle for PFE the way they do for the others, but a great long-term investment if you think rates will stay lower. PFE is mature, decent balance sheet, good valuation.

Show full opinionHide full opinion
Novavax Inc (NVAX-Q)
March 18, 2021

NVAX vs. PFE He'd absolutely go with PFE. Investors have been chasing growthy parts of the market and ignoring the stable areas. Vaccines don't move the needle for PFE the way they do for the others, but a great long-term investment if you think rates will stay lower. PFE is mature, decent balance sheet, good valuation.

John Zechner
Price
$219.540
Owned
Unknown
DON'T BUY
DON'T BUY
July 24, 2020
There is almost an arms race that is going on with respect to vaccine development. We need to wait to see how human testing is going to work out. There will be lots of volatility in the meantime. He is not interested in playing a specific name -- much like what happened with marijuana stocks. He would look to companies that will provide syringes instead.
Show full opinionHide full opinion
Novavax Inc (NVAX-Q)
July 24, 2020
There is almost an arms race that is going on with respect to vaccine development. We need to wait to see how human testing is going to work out. There will be lots of volatility in the meantime. He is not interested in playing a specific name -- much like what happened with marijuana stocks. He would look to companies that will provide syringes instead.
Showing 1 to 5 of 5 entries
  • «
  • 1
  • »

Novavax Inc(NVAX-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 4

Total Signals / Votes : 4

Stockchase rating for Novavax Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novavax Inc(NVAX-Q) Frequently Asked Questions

What is Novavax Inc stock symbol?

Novavax Inc is a American stock, trading under the symbol NVAX-Q on the NASDAQ (NVAX). It is usually referred to as NASDAQ:NVAX or NVAX-Q

Is Novavax Inc a buy or a sell?

In the last year, 4 stock analysts published opinions about NVAX-Q. 0 analysts recommended to BUY the stock. 4 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Novavax Inc.

Is Novavax Inc a good investment or a top pick?

Novavax Inc was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2021-07-22. Read the latest stock experts ratings for Novavax Inc.

Why is Novavax Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novavax Inc worth watching?

4 stock analysts on Stockchase covered Novavax Inc In the last year. It is a trending stock that is worth watching.

What is Novavax Inc stock price?

On 2021-07-23, Novavax Inc (NVAX-Q) stock closed at a price of $203.24.